CANY
GILD icon

Caxton Associates (New York)’s Gilead Sciences GILD Stock Holding History

Caxton Associates (New York)’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-100,000
Closed -$8.29M – 218
2014
Q2 		$8.29M Buy
100,000
+40,000
+67% +$3.11M 0.43% 48
2014
Q1 		$4.25M Buy
+60,000
New +$4.71M 0.26% 76

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caxton Associates (New York)'s GILD Position: Q4 2024 in Review

Caxton Associates (New York) reduced its Gilead Sciences (GILD) stake by 68% in Q4 2024, selling an estimated $1.07M and leaving 5,671 shares worth $524K. The position accounts for 0.02% of the portfolio, ranked #320.

Caxton Associates (New York) first reported a position in GILD in Q2 2013 and has held it in 13 quarters since. The position peaked at $66M in Q4 2022. 1,888 funds tracked by Wall St. Rank hold GILD as of Q4 2024.

  • Caxton Associates (New York) held 5,671 shares of Gilead Sciences worth $524K as of Q4 2024.
  • Caxton Associates (New York) sold 11,929 Gilead Sciences shares in Q4 2024, an estimated $1.07M.
  • Gilead Sciences made up 0.02% of Caxton Associates (New York)'s portfolio in Q4 2024, its #320 holding.
  • Caxton Associates (New York) first reported a position in Gilead Sciences in Q2 2013 and has held it in 13 quarters since.
  • Caxton Associates (New York)'s Gilead Sciences position peaked at $66M in Q4 2022.
  • 1,888 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.